Fluindapyr Fungicide by FMC Corporation Receives Registration in Brazil

23 Aug, 2023

Fluindapyr Fungicide by FMC Corporation Receives Registration in Brazil

FMC Corporation, a prominent player in the field of agricultural sciences, has recently secured Brazilian registration for fluindapyr, an innovative and comprehensive succinate dehydrogenase inhibitor (SDHI) fungicide. In Brazil, SDHI fungicides have gained immense significance, serving as essential tools for growers. The introduction of fluindapyr addresses the preventive control of a diverse array of detrimental diseases that commonly afflict Brazilian row crops, including rusts, leaf spots, and powdery mildew.

Marcelo Magurno, the FMC Brazil business director, expressed the company's intention to register several formulations of fluindapyr in Brazil, tailored for application in cotton, corn, and soybean crops. These formulations may include the ONSUVA® fungicide, a combination featuring difenoconazole. Research conducted by FMC indicates that fluindapyr stands as an effective fungicide and an excellent synergistic partner when combined with other fungicide active ingredients. Its compatibility with superior disease management strategies empowers Brazilian growers with the ability to exercise broad-spectrum preventive control against various fungal diseases. This comprehensive disease control is particularly vital as multiple diseases can assail crops simultaneously, potentially leading to yield losses and significant reductions in overall harvest.

The Brazilian registration represents another milestone in FMC's journey with fluindapyr, which has already been successfully registered in countries like Argentina, the United States, Paraguay, and South Korea. FMC has also initiated the process of registering fluindapyr formulations in multiple other countries, targeting key markets across various regions. Once these registrations are granted, agriculturalists worldwide will have access to innovative tools for disease management, complementing their crop cultivation programs and optimizing crop yields.

FMC is committed to introducing high-performance fluindapyr premixture products that provide adaptable and versatile resistance management, particularly excelling in tackling challenging-to-control diseases. Diane Allemang, FMC's executive vice president and chief marketing officer, stated that FMC's fluindapyr brands will empower global growers with the flexibility and adaptability they require to tailor their disease management strategies across diverse crops.

FMC Corporation stands as a global leader in agricultural sciences, dedicated to assisting growers in meeting the escalating demands of an expanding global population while navigating a changing environmental landscape. The company's innovative solutions encompass a wide range of crop protection measures, including biologicals, crop nutrition, digital tools, and precision agriculture. These solutions enable growers, crop advisors, and professionals in turf and pest management to address their most pressing challenges while maintaining economic viability and environmental sustainability. With a global workforce of approximately 6,600 individuals and operations across more than 100 sites worldwide, FMC is unwavering in its commitment to developing novel herbicides, insecticides, fungicides, formulations, and pioneering technologies that prioritize the health of the planet. For further information, please visit fmc.com and stay updated by following the company on LinkedIn® and Twitter®.

It's important to note that ONSUVA is a registered trademark of FMC Corporation and its affiliates. As always, it's recommended to carefully read and adhere to label directions. The products mentioned in this context might not be approved for sale or use in all states, countries, or jurisdictions.

In accordance with the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995, this release contains forward-looking statements that provide information beyond historical data. FMC has identified these statements through terms like "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "targets," "intends," or similar expressions that identify forward-looking statements within the context of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are grounded in management's present viewpoints and assumptions about future events, the future business environment, and the company's outlook based on the currently available information. This kind of statement involves a range of known and unknown risks, uncertainties, and other factors that can cause the actual results to substantially differ from any outcomes, levels of activity, performance, or achievements predicted or implied by any forward-looking statement. These factors encompass various elements, including risk factors and other cautionary statements stated in FMC's 2022 Form 10-K as submitted to the SEC, as well as other filings with the SEC and public communications. FMC urges readers to exercise caution and avoid placing undue reliance on any forward-looking statements, which are applicable solely as of their date of creation. FMC undertakes no obligation and disclaims any responsibility to update or revise any forward-looking statements to accommodate events or conditions occurring after the date of creation, except as required by law.